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ABSTRACT
The fibrinolysis proteinase tissue-type plasminogen activator
(tPA, also known as PLAT) triggers cell signaling and regulates
cell physiology. In PC12 cells, Schwann cells and macrophages, the
N-methyl-D-aspartate receptor (NMDA-R) mediates tPA signaling.
Plasminogenactivator inhibitor-1 (PAI1, alsoknownasSERPINE1) is a
rapidlyacting inhibitorof tPAenzymeactivity. Although tPA-initiated cell
signaling is not dependent on its enzyme active site, we show that
tPA signaling is neutralized by PAI1. In PC12 cells, PAI1 blocked the
ERK1/2 activation mediated by tPA as well as neurite outgrowth. In
Schwann cells, PAI1 blocked tPA-mediated ERK1/2 activation and
cell migration. In macrophages, PAI1 blocked the ability of tPA to
inhibit IκBα phosphorylation and cytokine expression. The cell
signaling activity of tPA–PAI1 complex was rescued when the
complex was formed with PAI1R76E, which binds to LRP1 with
decreased affinity, by pre-treating cells with the LRP1 antagonist
receptor-associated protein and upon LRP1 gene silencing. The
inhibitory role of LRP1 in tPA–PAI1 complex-initiated cell signaling was
unanticipated given the reported role of LRP1 as an NMDA-R co-
receptor in signaling responseselicitedby free tPAorα2-macroglobulin.
We conclude that PAI1 functions as an inhibitor not only of the enzyme
activity of tPA but also of tPA receptor-mediated activities.
KEY WORDS: Tissue-type plasminogen activator, Plasminogen
activator inhibitor-1, NMDA receptor, LDL receptor-related protein-1,
LRP1, Fibrinolysis, Cell signaling
INTRODUCTION
Tissue-type plasminogen activator (tPA) is a serine proteinase and
the major intravascular activator of fibrinolysis (Collen and Lijnen,
1991; Mosesson, 2005; Carmeliet et al., 1994). The structure of tPA
includes a fibronectin type I/finger domain, an epidermal growth
factor-like domain, two kringle domains and the serine proteinase
module, which are encoded by distinct exons in the PLAT gene
(Ny et al., 1984; Bode and Renatus, 1997). The multidomain
structure of tPA is critical for interactions with fibrin, extracellular
matrix proteins and cell surface receptors, which increase the catalytic
efficiency of plasminogen activation and control localization of
plasmin within tissues (van Zonneveld et al., 1986; Hoylaerts et al.,
1982; Moser et al., 1993; Hajjar et al., 1994; Miles et al., 2014).
tPA binding to extracellular matrix and cell surface proteins is also
important for generating plasmin at sites where it is protected from
its main inhibitors, α2-antiplasmin and α2-macroglobulin (α2M)
(Plow et al., 1986; Hall et al., 1991).
Through mechanisms that remain incompletely understood, tPA
initiates cell signaling and regulates cell physiology. In neurons, the
N-methyl-D-aspartate receptor (NMDA-R) functions as an essential
component of a pathway by which tPA regulates cell survival and
synaptic activity (Nicole et al., 2001; Wu et al., 2013; Yepes, 2015;
Chevilley et al., 2015; Lesept et al., 2016; Jeanneret and Yepes,
2017; Liot et al., 2006). Because tPA binds to an ectodomain in the
NMDA-R GluN1/NR1 (also known as GRIN1) subunit (Nicole
et al., 2001; Lesept et al., 2016), the NMDA-R probably represents a
true cell signaling receptor for tPA in neurons. The NMDA-R also
functions as a tPA receptor in cells other than neurons, including
macrophages and Schwann cells (SCs) (Mantuano et al., 2017,
2015). In macrophages, tPA-activated cell signaling suppresses
innate immunity (Mantuano et al., 2017). In SCs, tPA promotes
cell migration (Mantuano et al., 2015). tPA binding to the NMDA-R
regulates the contractility of pulmonary arterial rings, suggesting
that vascular smooth muscle cells respond to tPA (Nassar et al.,
2011). In SCs, macrophages and PC12 cells, enzymatically active
tPA (EA-tPA; wild-type protein) and enzymatically inactive tPA
(EI-tPA; tPA with a S478A mutation, see Materials and Methods)
demonstrate equivalent signaling activity, suggesting that domains
other than the tPA serine proteinase module are involved
(Mantuano et al., 2017, 2015, 2013). In support of this
hypothesis, Parcq et al. (2013) identified an amino acid mutation
in the Kringle-2 domain of tPA, which nullifies NMDA-R-
mediated activities in cortical neurons.
When tPA initiates cell signaling, LDL receptor-related protein-1
(LRP1) apparently functions as a NMDA-R co-receptor (Yepes,
2015; Mantuano et al., 2015, 2013; Samson et al., 2008; Echeverry
et al., 2010). tPA binds directly to the extracellular α-chain of LRP1
(Bu et al., 1992). In PC-12 cells, N2a cells and SCs, the LRP1
antagonist, receptor-associated protein (RAP, also known as
LRPAP1), does not block tPA signaling; however, the
concentration of tPA required to observe cell signaling is
increased (Mantuano et al., 2015, 2013). It is possible that tPA
bridges LRP1 to the NMDA-R to effectively trigger cell signaling.
LRP1 and the NMDA-R also may be bridged on the intracellular
side of the plasma membrane by the bi-functional adaptor protein
PSD-95 (also known as DLG4) (Mantuano et al., 2013; May et al.,
2004; Martin et al., 2008; Nakajima et al., 2013). Other LRP1
ligands, such as α2M, trigger cell signaling in an NMDA-R-
dependent manner; however, unlike tPA, α2M appears to have an
absolute requirement for LRP1 in order to signal (Mantuano et al.,
2013, 2015; Bacskai et al., 2000; Qiu et al., 2002).
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inhibitor of both tPA and urokinase-type plasminogen activator
(uPA; also known as PLAU) (Hekman and Loskutoff, 1988). When
tPA or uPA bind to PAI1, the complex binds to LRP1 with increased
affinity (KD of 5-10 nM), reflecting the unmasking of a nascent
LRP1-binding site in PAI1 (Herz et al., 1992; Orth et al., 1992;
Stefansson et al., 1998). PAI1 has diverse effects on cell physiology,
some of which are unrelated to its role as an inhibitor of tPA and
uPA. For example, binding of PAI1 to vitronectin regulates cell
adhesion mediated by integrins and the urokinase receptor (uPAR)
(Stefansson and Lawrence, 1996; Czekay et al., 2003; Deng et al.,
1996). In cancer cells, PAI1 alters the cell signaling response
triggered by uPA, so that uPA is converted into a cancer cell
mitogen (Webb et al., 2001). When the PAI1 gene is deleted in
mice, cancer invasion and angiogenesis are inhibited (Bajou et al.,
1998). Furthermore, in at least seven different types of human
malignancy, high PAI1 expression is associated with an unfavorable
prognosis, as determined by analysis of datasets of The Cancer
Genome Atlas, summarized in the Protein Atlas (Uhlen et al., 2017).
Plasma PAI1 levels are increased in conditions associated with
inflammation, including metabolic syndrome, cardiovascular
disease and diabetes (De Taeye et al., 2005; Devaraj et al., 2003;
Alessi and Juhan-Vague, 2006).
In the present study, we examined the effects of PAI1 on
tPA-initiated cell signaling in three separate cell types. In all three
model systems, PAI1 neutralized the signaling activity of tPA.
In macrophages, PAI1 blocked the anti-inflammatory activity of
tPA. In PC12 cells, PAI1 blocked the effects of tPA on neurite
outgrowth, and in SCs, PAI1 inhibited tPA-induced cell migration.
Mechanistically, the ability of PAI1 to block tPA signaling required
LRP1. Accordingly, the cell signaling activity of tPA–PAI1 complex
was rescued using three separate approaches: (1) upon forming a tPA–
PAI1 complex with mutated PAI1 (PAI1R76E), which binds to LRP1
with greatly decreased affinity (Stefansson et al., 1998); (2) upon
treating cells with tPA–PAI1 complex in the presence of RAP; and
(3) upon silencing LRP1 gene expression. Our results demonstrate
that PAI1 functions not only as an inhibitor of the enzymatic activity
of tPA but also as a regulator of receptor-mediated tPA activities.
RESULTS
PAI1 neutralizes the effects of EA-tPA on PC12 cell signaling
and neurite outgrowth
To begin, we studied human PAI1, which is mutated to enhance
stability and expressed in E. coli and thus not glycosylated.
To confirm that the PAI1 was active, we incubated EA-tPAwith an
equimolar concentration of PAI1 or a 3-fold molar excess of PAI1
for 30 min. tPA activity was assessed in a coupled enzyme assay
with purified human plasminogen and the plasmin-specific substrate
H-D-Val-Leu-Lys-p-nitroanilide (S-2251). In the absence of PAI1,
time-dependent plasminogen activation and S-2251 hydrolysis
were observed (Fig. 1A). PAI1 at both concentrations completely
neutralized plasminogen activation, indicating complex formation.
Equivalent results were obtained when EA-tPA was pre-incubated
with glycosylated PAI1 (gPAI1) expressed in insect cells or with
PAI1R76E (Stefansson et al., 1998) (results not shown). Unless
otherwise stated, tPA–PAI1 complexes were formed using a 3-fold
molar excess of PAI1.
In PC12 cells, tPA activates ERK1 and ERK2 (ERK1/2, also
known asMAPK3 andMAPK1, respectively) through a pathway that
requires the NMDA-R (Mantuano et al., 2013).We treated PC12 cells
for 10 min with increasing concentrations of EA-tPA or preformed
EA-tPA–PAI1 complex (12–100 nM). EA-tPA, at each concentration
studied, activated ERK1/2 (Fig. 1B). EA-tPA–PAI1 complex failed
to activate ERK1/2 at the equivalent concentrations. Free PAI1
(36 nM) also failed to activate ERK1/2.
EI-tPA and EA-tPA activate ERK1/2 in PC12 cells equivalently,
suggesting that the enzyme active site of tPA is not involved
(Mantuano et al., 2013). To confirm that PAI1 does not block the
signaling activity of EA-tPA by neutralizing its enzymatic activity,
we treated EA-tPA with the irreversible active site inhibitor
4-(2-aminoethyl) benzene sulfonyl fluoride HCl (AEBSF)
(1.0 mM) for 2 h. Complete neutralization of the enzymatic
activity of EA-tPA was confirmed in coupled enzyme assays with
plasminogen and S-2251 (results not shown). Free AEBSF was
removed by extensive dialysis. AEBSF-treated EA-tPA activated
ERK1/2 equivalently to non-treated EA-tPA (Fig. 1C). Free AEBSF
(10 μM) did not activate ERK1/2.
To test the role of the NMDA-R in tPA signaling in PC12 cells,
cells were treated with the non-competitive NMDA-R antagonist
MK801. ERK1/2 activation in response to EA-tPA was blocked
(Fig. 1D), as anticipated (Mantuano et al., 2013). EA-tPA–PAI1
complex failed to trigger cell signaling in MK801-treated PC12
cells and in cells that were not treated with MK801.
Next, we studied PC12 cell neurite outgrowth, a process that
requires ERK1/2 activation (Vaudry et al., 2002). Cells were treated
with EA-tPA (12 nM), EI-tPA (12 nM), preformed EA-tPA–PAI1
complex (12 nM), free PAI1 (36 nM) or nerve growth factor-β
(NGFβ) (50 ng/ml), as a positive control. Neurite outgrowth was
allowed to occur for 48 h in serum-free medium (SFM).
Representative images are shown in Fig. 1E, and the results of
four separate experiments are summarized in Fig. 1F. Mean neurite
length was significantly increased by both EA-tPA and EI-tPA.
The responses observed with EA-tPA and EI-tPA were similar in
magnitude to those observed with NGFβ. Preformed EA-tPA–PAI1
complex failed to promote neurite outgrowth. Free PAI1 (36 nM)
was also inactive.
PAI1 blocks the effects of EA-tPA on SC signaling and
cell migration
EI-tPA activates cell signaling in SCs and the response requires the
NMDA-R (Mantuano et al., 2015). Fig. 2A shows that EA-tPA
(12 nM) activated ERK1/2 in SCs. The response was evident at
10 min and sustained through 60 min. By contrast, preformed
EA-tPA–PAI1 complex (12 nM) failed to activate ERK1/2.
Free PAI1 (36 nM) also was inactive. MK801 inhibited ERK1/2
activation mediated by EA-tPA (Fig. 2B), confirming an essential
role for the NMDA-R (Mantuano et al., 2015).
ERK1/2 activation in SCs is typically associated with increased
cell migration (Mantuano et al., 2008, 2010, 2015). We therefore
treated SCs with EA-tPA (12 nM), free PAI1 (36 nM) or preformed
EA-tPA–PAI1 complex (12 nM), and tested whether cell migration
was regulated by allowing the cells to migrate in Transwell
chambers for 4 h. Representative images of the underside surfaces
of membranes are shown in Fig. 2C, and the results of four separate
experiments are summarized in Fig. 2D. EA-tPA stimulated SC
migration more than 4-fold. By contrast, preformed EA-tPA–PAI1
complex and free PAI1 had no effect on SC migration.
PAI1 neutralizes the effects of EA-tPA on the response to
LPS in macrophages
We previously demonstrated that EI-tPA and EA-tPA inhibit the
ability of lipopolysaccharide (LPS) to induce sustained IκBα
phosphorylation and cytokine expression in bone marrow-derived
macrophages (BMDMs) (Mantuano et al., 2016, 2017). Using
equivalent methods, we compared the effects of free EA-tPA and
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preformed EA-tPA–PAI1 complex. Fig. 3A shows that the
treatment of BMDMs with LPS (0.1 μg/ml) for 1 h induced
phosphorylation of IκBα (encoded by NFKBIA) and a decrease in
the total abundance of IκBα. These events report NFκB activation
(Ghosh and Karin, 2002).
When BMDMs were treated with LPS together with EA-tPA
(12–24 nM), IκBα phosphorylation and the decrease in total IκBα
were blocked. By contrast, EA-tPA–PAI1 complex (0.2–24 nM)
failed to reverse the effects of LPS on IκBα phosphorylation
and abundance. Free PAI1 (72 nM) also had no effect. In the
absence of LPS, EA-tPA–PAI1 complex (24 nM) did not cause
IκBα phosphorylation.
Next, BMDMs were treated with LPS (0.1 µg/ml), EA-tPA
(12 nM) or EA-tPA–PAI1 complex (12 nM), alone or in
combination. After 6 h, expression of pro-inflammatory cytokines
was determined by real-time quantitative PCR (RT-qPCR). In the
Fig. 1. PAI1 blocksERK1/2 activation and neurite outgrowth inducedbyEA-tPA inPC12 cells. (A) The following proteins were incubated with S-2251 (0.2 mM):
plasminogen (0.2 μM) (black star); PAI1 (12 nM) (open green square); PAI1 (36 nM) (open blue triangle); EA-tPA (12 nM) (open red circle); EA-tPA–PAI1 complex
formedwith anequimolarconcentrationofEA-tPAandPAI1 (12 nM) (open teal diamond);EA-tPA–PAI1complex formedwith a 3-foldmolarexcessofPAI1 (12 nMEA-
tPA) (open orange inverted triangle); PAI1 (12 nM) plus plasminogen (0.2 μM) (closed green square); PAI1 (36 nM) plus plasminogen (0.2 μM) (closed blue triangle);
EA-tPA (12 nM) plus plasminogen (0.2 μM) (closed red circle); EA-tPA–PAI1 complex formed with an equimolar concentration of EA-tPA and PAI1 plus plasminogen
(0.2 μM) (closed teal diamond); and EA-tPA–PAI1 complex formed with a 3-fold molar excess of PAI1 plus plasminogen (0.2 μM) (closed orange inverted triangle).
Theabsorbanceat 405 nmwasdeterminedevery10 min for1 h.Not all resultscanbedistinguishedowing to their similarity, exceptEA-tPAplusplasminogen. (B)PC12
cells were serum starved for 4 h and then treated with increasing concentrations of EA-tPA (12–100 nM) or preformed EA-tPA–PAI1 complex for 10 min. Additional
cultureswere treatedwith freePAI1 (36 nM) or vehicle. Equal amounts of cellular protein (10 μg)were subjected toSDS-PAGE. Immunoblot analysiswas performed to
detect phosphorylatedERK1/2 (p-ERK) and total ERK1/2 (T-ERK). (C) EA-tPAwas treatedwithAEBSF (1 mM) for 3 h and then subjected to 1:2500 (vol/vol) dialysis.
PC12 cells were treated with EA-tPA (12 nM), AEBSF-inactivated EA-tPA (12 nM), free AEBSF (10 μM) or vehicle for 10 min. Immunoblot analysis was performed
todetect p-ERK1/2andT-ERK1/2. (D)PC12cellswerepre-treatedwithMK801 (1 µM)or vehicleand thenwith freePAI1 (36 nM),EA-tPA (12 nM),preformedEA-tPA-
PAI1 complex (12 nM)or vehicle for 10 min. Immunoblot analysiswas performed todetect p-ERK1/2andT-ERK1/2. (E)PC12 cellswere treatedwithEA-tPA (12 nM),
EI-tPA (12 nM), PAI1 (36 nM), preformed EA-tPA–PAI1 complex (12 nM), NGFβ (50 ng/ml) or vehicle (Veh) for 48 h. Neurite outgrowth was assessed by phase-
contrastmicroscopy.Representative imagesare shown.Scalebar:40 μm. (F)Neuriteoutgrowth resultswerequantified.Neurite lengthwasdeterminedusing ImageJ.
Data are expressed as the mean±s.e.m. (n=4, ***P<0.001 compared with the vehicle control; one-way ANOVA and Dunnett’s test).
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absence of other reagents, LPS induced expression of the mRNAs
encoding tumor necrosis factor (TNF), chemokine C-C motif ligand
3 (CCL3), interleukin-1β (IL-1β) and interleukin-6 (IL-6) (Fig. 3B).
EA-tPA blocked cytokine expression in response to LPS, as
anticipated (Mantuano et al., 2017). By contrast, EA-tPA–PAI1
complex failed to block LPS-induced cytokine expression.
gPAI1 behaves equivalently to PAI1 expressed in bacteria
The results presented thus far suggest that when EA-tPA binds PAI1,
the PAI1 disallows a key interaction required for initiation of cell
signaling and regulation of cell physiology by tPA. To determine
whether this PAI1 activity is unique to the non-glycosylated form of
the Serpin, we examined cell signaling in response to EA-tPA–PAI1
complex formed with gPAI1, expressed in insect cells. EA-tPA–
gPAI1 complex failed to activate ERK1/2 in PC12 cells (Fig. 4A).
EA-tPA–gPAI complex also failed to activate ERK1/2 in SCs
(Fig. 4B). In both studies, free EA-tPA demonstrated the anticipated
cell signaling activity.
PAI1 does not neutralize the cell signaling activity of EI-tPA
In EI-tPA, mutation of the active site serine (S478A) blocks the
principal interaction that leads to irreversible complex formation
between tPA and PAI1 (Hekman and Loskutoff, 1988). We
therefore performed studies to test whether PAI1 antagonizes the
cell signaling activity of EI-tPA. EI-tPA was incubated with a
3-fold molar excess of PAI1 for 30 min. PC12 cells were treated
with this preparation (12 nM EI-tPA, 36 nM PAI1) for 10 min or
with EI-tPA (12 nM), EA-tPA (12 nM), preformed EA-tPA–PAI1
complex (12 nM) or free PAI1 (36 nM). Fig. 5A shows that both
EA-tPA and EI-tPA activated ERK1/2 in PC12 cells, as
anticipated (Mantuano et al., 2013). EA-tPA–PAI1 complex
failed to activate ERK1/2. By contrast, EI-tPA that was pre-
incubated with a 3-fold molar excess of PAI1 demonstrated
unchanged activity, inducing ERK1/2 phosphorylation to the
same extent as EI-tPA that was not exposed to PAI1.
Next, we examined SCs. EI-tPA (12 nM) activated ERK1/2 in
SCs and pre-incubating EI-tPA (12 nM) with PAI1 (36 nM) for
30 min failed to inhibit the cell signaling activity of the EI-tPA
(Fig. 5B). In cell migration studies, EI-tPA (12 nM) and EI-tPA
(12 nM) that was pre-incubated with PAI1 (36 nM) for 30 min
demonstrated equivalent activity, increasing SCmigration by∼4-fold
(Fig. 5C,D). Free PAI1 failed to stimulate SC migration.
Blocking the interaction of EA-tPA–PAI1 complex with LRP1
rescues its cell signaling activity
EA-tPA–PAI1 complex was formed with PAI1R76E. This complex
binds to LRP1 with substantially decreased affinity compared
with EA-tPA–PAI1 complex formed with wild-type PAI1
(Stefansson et al., 1998). EA-tPA–PAI1R76E complex (12 nM)
activated ERK1/2 in PC12 cells and the magnitude of the response
Fig. 2. PAI1 blocks ERK1/2 activation and cell migration induced by EA-tPA in SCs. (A) Primary cultures of SCs were serum-starved for 1 h and then treated
with free PAI1 (36 nM), EA-tPA (12 nM), preformed EA-tPA–PAI1 complex (12 nM) or vehicle (Veh) for various times up to 1 h. Immunoblot analysis was
performed to detect phosphorylated ERK1/2 (p-ERK) and total ERK1/2 (T-ERK). (B) SCs were pre-treated with MK801 (1 µM) or with vehicle for 30 min and
then with PAI1 (36 nM), EA-tPA (12 nM), preformed EA-tPA–PAI1 complex (12 nM) or vehicle for 10 min. Cell extracts were subject to immunoblot analysis
to detect p-ERK1/2 and T-ERK1/2. (C) SCs were treated with PAI1 (36 nM), EA-tPA (12 nM), preformed EA-tPA–PAI1 complex (12 nM) or vehicle. SC migration
was studied. Migration was allowed to proceed for 4 h at 37°C. Representative images of SCs that migrated across Transwell membranes to the lower
membrane surfaces are shown. (D) Quantification of cell migration results. Data are expressed as the mean±s.e.m. (n=4, ***P<0.001 compared with the vehicle
control; one-way ANOVA and Dunnett’s test).
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was equivalent to that observed with free EA-tPA (12 nM)
(Fig. 6A).
Next, we pre-treated PC12 cells with 150 nM RAP for 30 min
before introducing EA-tPA–PAI1 complex formed with wild-type
PAI1. RAP binds to the ligand-binding domains of LRP1 and
inhibits binding of other ligands (Williams et al., 1992). In PC12
cells pre-treated with RAP, EA-tPA–PAI1 complex formed with
wild-type PAI1 (12 nM) activated ERK1/2 (Fig. 6B). EA-tPA–
PAI1R76E complex activated ERK1/2 in the presence or absence
of RAP.
Finally, we silenced LRP1 gene expression in PC12 cells, using
our established method (Mantuano et al., 2013). Control cells were
transfected with non-targeting control (NTC) siRNA. LRP1 gene
silencing resulted in a 72±3% (mean±s.d.) decrease in LRP1 protein
as determined by immunoblot analysis (Fig. 6C) and densitometry.
In LRP1 gene-silenced cells, 12 nM of EA-tPA–PAI1 complex,
formed with wild-type PAI1, activated ERK1/2 comparably to
EA-tPA. In control cells transfected with NTC siRNA, ERK1/2
activation was observed in response to EA-tPA but not EA-tPA–
PAI1 complex. Collectively, these results demonstrate that LRP1
inhibits the cell signaling activity of EA-tPA–PAI1 complex.
EA-tPA and EA-tPA-PAI1 complex bind to
immunopurified NMDA-R
We coupled NMDA-R NR1 subunit-specific antibody (NR1-Ab) to
Protein G–Dynabeads and immunopurified NMDA-R from extracts
of mouse cortex. As a control, we coupled non-specific IgG
(NS-IgG) to Protein G–Dynabeads and incubated these beads with
the equivalent mouse cortical extracts. Immunoblot analysis for NR1
confirmed that NMDA-R was recovered selectively in association
with anti-NR1 antibody but not NS-IgG (Fig. 7A).
NR1-Ab and NS-IgG were ‘pre-loaded’ with NMDA-R
by incubation with mouse cortical extracts, washed and then
incubated with 125I-EA-tPA (12 nM). Binding of 125I-EA-tPA to
pre-loaded NR1-Ab was significantly increased compared with
its binding to pre-loaded NS-IgG (P<0.01; n=6, unpaired
Fig. 3. PAI1 neutralizes the ability of EA-tPA to counteract
the effects of LPS in BMDMs. (A) BMDMs from C57BL/6J
mice were treated with LPS (0.1 μg/ml), LPS (0.1 μg/ml) plus
EA-tPA (0.2–24 nM), LPS (0.1 μg/ml) plus preformed EA-tPA–
PAI1 complex (0.2–24 nM), preformed EA-tPA–PAI1 complex
(24 nM) in the absence of LPS, LPS (0.1 μg/ml) plus free PAI1
(36 nM), or vehicle (Veh) for 1 h. Immunoblot analysis was
performed to detect phosphorylated IκBα (p-IκBα) and total
IκBα. Blots were re-probed for β-actin as a control for load.
(B) BMDMs were treated with LPS (0.1 μg/ml), EA-tPA
(12 nM), preformed EA-tPA–PAI1 complex (12 nM), LPS
(0.1 μg/ml) plus EA-tPA (12 nM), LPS (0.1 μg/ml) plus
preformed EA-tPA–PAI1 complex (12 nM) or vehicle for 6 h.
Expression of the mRNAs encoding TNF (TNFα), CCL3, IL-1β
and IL-6 was determined (mean±s.e.m.; n=5; *P<0.05,
***P<0.001, N.S., not statistically significant; one-way ANOVA
with Tukey’s post hoc test).
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Student’s t-test) (Fig. 7B). 125I-tPA–PAI1 complex also bound at
significantly increased levels to pre-loaded NR1-Ab compared
with its binding to NS-IgG (P<0.01, n=6, unpaired Student’s
t-test) (Fig. 7C). When all four binding studies were analyzed
collectively by ANOVAwith a Tukey’s post hoc test, it was found
that binding of 125I-tPA–PAI1 complex to pre-loaded NR1-Ab
was significantly lower than that of 125I-tPA (P<0.01).
To test whether the NMDA-R is required for activation of cell
signaling by EA-tPA–PAI1 complex when LRP1 is neutralized, we
treated PC12 cells with MK801 and then with EA-tPA–PAI1R76E
complex (12 nM). MK801 blocked ERK1/2 activation by
EA-tPA–PAI1R76E complex (Fig. 7D).
DISCUSSION
Elevated plasma PAI1 is associated with diverse diseases that
have an important inflammatory component, including thrombo-
atherosclerotic cardiovascular disease, metabolic syndrome and
diabetes (De Taeye et al., 2005; Devaraj et al., 2003; Alessi and
Juhan-Vague, 2006). Potent pro-inflammatory mediators such as
LPS and TNF induce PAI1 expression in mice (Sawdey and
Loskutoff, 1991). C-reactive protein, a biomarker of inflammation,
increases PAI1 expression by endothelial cells in culture (Devaraj
et al., 2003). It is thus well supported that PAI1 is increased in a
variety of pathophysiologic states that involve inflammation.Whether
PAI1 is a biomarker of inflammation or contributes actively to the
process remains incompletely understood.
We previously identified a receptor-mediated pathway in
macrophages by which tPA suppresses innate immunity and
inflammation (Mantuano et al., 2016, 2017). This pathway
requires NMDA-R (Mantuano et al., 2017), as does tPA-initiated
cell signaling in SCs and PC12 cells (Mantuano et al., 2013, 2015).
The results presented here and elsewhere (Mantuano et al., 2013,
2015, 2017) demonstrate that the enzyme activity of tPA is not
required for activation of cell signaling via the NMDA-R.
Nevertheless, when tPA forms a complex with PAI1, not only is
the enzyme activity of EA-tPA neutralized, but also the ability of
EA-tPA to trigger NMDA-R-dependent cell signaling. As a result,
PAI1 reverses the activity of EA-tPA as a stimulant of neurite
outgrowth in PC12 cells, as a stimulant of SC migration and as a
suppressor of LPS-induced cytokine expression in BMDMs.
Fig. 4. Glycosylated PAI1 blocks EA-tPA-initiated cell signaling. (A) PC12
cells were treated with gPAI1 (36 nM), EA-tPA (12 nM), preformed EA-tPA–
gPAI1 complex (12 nM) or vehicle for the indicated times. Immunoblot analysis
was performed to detect phosphorylated ERK1/2 (p-ERK) and total ERK1/2
(T-ERK). (B) SCs were treated with gPAI1 (36 nM), EA-tPA (12 nM), EA-tPA–
gPAI1 complex (12 nM) or vehicle for 10 min. Immunoblot analysis was
performed to detect p-ERK1/2 and T-ERK1/2.
Fig. 5. The effects of EI-tPA on ERK1/2 activation and SC
migration are not inhibited by PAI1. (A) PC12 cells were treated
for 10 min with PAI1 (36 nM), EA-tPA (12 nM), EI-tPA (12 nM),
preformed EA-tPA–PAI1 complex (12 nM), EI-tPA (12 nM) that
was pre-incubated with 36 nMPAI1, or vehicle (Veh). Immunoblot
analysis was performed to detect phosphorylated ERK1/2
(p-ERK) and total ERK1/2 (T-ERK). (B) SCs were treated for
10 min with free PAI1 (36 nM), EI-tPA (12 nM), EI-tPA (12 nM)
that was pre-incubated with PAI1 (36 nM), or vehicle. Immunoblot
analysis was performed to detect p-ERK1/2 and T-ERK1/2.
(C) SCs were treated with PAI1 (36 nM), EI-tPA (12 nM), EI-tPA
(12 nM) that was pre-incubated with PAI1 (36 nM), or vehicle.
Migration was allowed to proceed for 4 h at 37°C. Representative
images of SCs that migrated to the lower membrane surfaces are
shown. (D) Quantification of cell migration results. Data are
expressed as themean±s.e.m. (n=4, **P<0.01 compared with the
vehicle control; one-way ANOVA and Dunnett’s test).
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Equivalent results were obtained with non-glycosylated PAI1 and
with gPAI1. We conclude that PAI1 functions to neutralize the
proteinase activity of tPA and various activities of tPA resulting
from interaction with the NMDA-R.
In PC12 cells and SCs, LRP1 is not essential for tPA signaling;
however, neutralizing the activity of LRP1 with RAP increases the
concentration of tPA required to trigger a signaling response
(Mantuano et al., 2013, 2015). Activation of cell signaling by α2M
requires both the NMDA-R and LRP1 in SCs and PC12 cells;
α2M-initiated cell signaling is blocked by RAP in these cells
(Mantuano et al., 2013, 2015; Bacskai et al., 2000; Qiu et al., 2002).
The function of LRP1 in regulating tPA–PAI1 complex-induced
cell signaling is thus a new discovery. By using three distinct
approaches, we demonstrate that LRP1 inhibits cell signaling
by tPA–PAI1 complex. The signaling activity of tPA–PAI1
complex was rescued by forming the complex with PAI1R76E, by
silencing LRP1 gene expression and by treating cells with RAP.
Upon de-repression, the signaling activity of tPA–PAI1 complex
required NMDA-R, similar to what is seen with free tPA.
Significant binding of tPA–PAI1 complex to immuno-purified
NMDA-R was demonstrated. The extent of binding of tPA–PAI1
complex to immunopurified NMDA-Rmight be less than that of free
tPA; however, this conclusion should be interpreted cautiously
Fig. 6. Neutralizing LRP1 de-represses the signaling activity of
EA-tPA–PAI1 complex. (A) PC12 cells were treated with PAI1R76E (36 nM),
EA-tPA (12 nM), preformed EA-tPA–PAI1R76E complex (12 nM) or vehicle
for 10 min. Immunoblot analysis was performed to detect phosphorylated
ERK1/2 (p-ERK) and total ERK1/2 (T-ERK). (B) PC12 cells were pre-treated
with RAP (150 nM) or vehicle for 30 min and then with PAI1 (36 nM), PAI1R76E
(36 nM), EA-tPA (12 nM), preformed EA-tPA–PAI1 complex (12 nM),
preformed EA-tPA–PAI1R76E complex (12 nM) or vehicle for 10 min.
Cell extracts were subject to immunoblot analysis to detect p-ERK1/2 and
T-ERK1/2. (C) PC12 cells in which LRP1 was silenced and control cells,
transfected with NTC siRNA, were treated with EA-tPA (12 nM), preformed
EA-tPA–PAI1 complex (12 nM) or vehicle for 60 min. Immunoblot analysis was
performed to detect p-ERK1/2, T-ERK1/2 and LRP1.
Fig. 7. PAI1 inhibits binding of EA-tPA to immunopurified NMDA-R.
(A) Extracts of mouse cortex were incubated with NMDA-R NR1
subunit-specific antibody (NR1) or with NS-IgG (IgG) coupled to Protein-G–
Dynabeads. Bound proteins were immunoprecipitated in an acidic solution,
neutralized and subjected to immunoblot analysis to detect NMDA-R NR1
subunit (IP). As a control, the original extracts were subjected to
immunoblot analysis to detect the NR1 subunit and actin prior to incubation
with Protein-G–Dynabeads (input) and after immunoprecipitation (cleared
extract). (B) NMDA-R NR1 subunit-specific antibody (NR1) or NS-IgG (IgG)
coupled to Protein-G–Dynabeads were pre-incubated with mouse cortical
extracts, washed extensively and incubated with 125I-EA-tPA (12 nM) for 2 h at
4°C. The beads were washed extensively again. 125I-EA-tPA that was
associated with the Dynabeads was determined in a γ-irradiation counter
(mean±s.e.m., n=6; **P<0.01, unpaired t-test). (C) 125I-EA-tPA–PAI1 complex
was incubated with pre-loaded NMDA-R NR1 subunit-specific antibody (NR1)
or NS-IgG (IgG) coupled to Protein-G–Dynabeads for 2 h at 4°C. The beads
were washed. 125I-EA-tPA–PAI1 complex that was associated with the
Dynabeads was determined in a γ-irradiation counter (mean±s.e.m., n=6;
**P<0.01, unpaired t-test). (D) PC12 cells were pre-treated withMK801 (1 µM) or
with vehicle for 30 min and then with EA-tPA (12 nM), EA-tPA–PAI1R76E
complex (12 nM) or vehicle for 10 min. The presence of phosphorylated ERK1/2
(p-ERK) and total ERK1/2 (T-ERK) were determined by immunoblot analysis.
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because only one concentration of ligand was studied and
immunopurified NMDA-R might behave differently than
membrane-anchored NMDA-R.
We considered the possibility, given the high affinity of
tPA–PAI1 complex for LRP1 (Stefansson et al., 1998), that signaling
by the tPA–PAI1 complex is blocked by LRP1 because LRP1 rapidly
clears tPA–PAI1 complex from the cellular microenvironment and
thus, prevents binding to NMDA-R. The maximum uptake and
degradation of high-affinity ligands by LRP1 in cells with greater than
105 copies of LRP1, has been estimated at 50 fmol/106 cells per
minute (Iadonato et al., 1993;Weaver et al., 1996). In our experiments
with nearly confluent cultures of PC12 cells (∼0.5×106 cells) and
12 nM tPA–PAI1 complex in 2.0 ml medium, 24,000 fmols of
tPA–PAI1 complex were present. Applying published ligand uptake
rates for LRP1, the concentration of the tPA–PAI1 complex would
have been expected to decrease from 12 nM to no lower than 11.9 nM
in our ERK1/2 activation experiment. Thus, we do not view depletion
of tPA–PAI1 complex from the culture medium as an explanation for
the lack of signaling activity by tPA–PAI1 complex. In support of this
conclusion, activated α2M, which binds to LRP1 with high affinity
(KD∼1.0 nM) (Weaver et al., 1996; Van Leuven et al., 1979; Hussaini
et al., 1990), triggers cell signaling in PC12 cells and SCs when
present at a concentration of 10 nM.
Identifying the mechanism by which LRP1 selectively inhibits
the cell signaling activity of tPA–PAI1 complex, while promoting
cell signaling initiated by free tPA or activated α2M, will require
further investigation. We speculate that binding of tPA–PAI1
complex to LRP1 may sterically hinder the complex from engaging
its binding site on the NMDA-R. PAI1-binding to EA-tPA and
the resulting high affinity interaction with LRP1 also may inhibit
distribution of tPA–PAI1 complex into lipid rafts, where tPA-initiated
cell signaling apparently occurs (Laudati et al., 2016).
PAI1 had no effect on the cell signaling activity of EI-tPA or the
ability of EI-tPA to stimulate SCmigration. This is an important result
because tPA has been reported to associate non-covalently with PAI1
through exosite interactions (Ibarra et al., 2004). Apparently, exosite
interactions do not trigger PAI1 conformational change, which is
required to reveal the cryptic high-affinity LRP1-binding site in
PAI1 (Herz et al., 1992; Orth et al., 1992; Stefansson et al., 1998).
As a result, the pathway we have uncovered, in which binding of
tPA–PAI1 complex to LRP1 inhibits cell signaling initiated by the
complex, is not operational.
We hypothesize that the activity of PAI1 observed here, as a
regulator of tPA activities mediated by the NMDA-R in PC12 cells,
SCs and BMDMs, may be observed in other cells in which tPA
binds to the NMDA-R, such as neurons (Nicole et al., 2001;
Wu et al., 2013; Yepes, 2015; Chevilley et al., 2015; Lesept et al.,
2016; Jeanneret and Yepes, 2017). However, we also recognize that
in addition to the NMDA-R, other receptors have been implicated in
tPA signaling. One example is Annexin A2 (Siao and Tsirka, 2002;
Ortiz-Zapater et al., 2007; Lin et al., 2012; Lin and Hu, 2017).
Understanding how PAI1 regulates receptor-mediated activities of
tPA, which involve receptors such as Annexin A2, is an important
future challenge.
MATERIALS AND METHODS
Proteins and reagents
Human EA-tPA, which is produced in CHO cells and is 95% in the two-chain
form, and human EI-tPA, which carries the S478Amutation and is 90% in the
single-chain form, were fromMolecular Innovations. PAI1, which is mutated
to enhance stability and expressed in Escherichia coli, gPAI1, which is
expressed in insect cells, and PAI1R76E were from Molecular Innovations.
Plasminogen was purified from human plasma as previously described
(Gonias et al., 1982). Endotoxin-free, monomeric RAP was provided by
Dr Travis Stiles (Novoron Biosciences, San Diego, CA). NGFβ was from
Invitrogen. LPS serotype 055:B5 from E. coli was from Sigma-Aldrich.
H-D-Val-Leu-Lys-p-nitroanilide (S-2251) was from Molecular Innovations.
Dizocilpine (MK801) was from Cayman Chemicals. Type IV collagen,
poly-D-lysine (PDL), AEBSF and fibronectin were from Sigma-Aldrich.
Cell culture model systems
Rat PC12 pheochromocytoma cells were obtained from the ATCC
(CRL-1721™) and subjected to quality-control tests by the ATCC. The
PC12 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM,
high glucose; Gibco) containing 10% heat-inactivated fetal bovine serum
(FBS; Gibco), 5% heat-inactivated horse serum (Hyclone), penicillin
(100 units/ml) and streptomycin (1 mg/ml), in plates coated with 0.01 mg/ml
type IV collagen. Cells were passaged no more than eight times.
SCswere isolated from the sciatic nerves of 1-day-old SpragueDawley rats.
The SCs were enriched and separated from fibroblasts using fibronectin-
specific antibody and rabbit complement cytolysis. Final preparations
consisted of 98% SCs, as determined by immunofluorescence microscopy
for S100β, which is a specific SCmarker (Mantuano et al., 2015). Primary SC
cultures were maintained in plates coated with 1.0 µg/ml PDL in low-glucose
DMEM containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin,
21 μg/ml bovine pituitary extract (Sigma-Aldrich) and 4 μM forskolin
(Thermo Scientific), and were passaged no more than six times before
conducting experiments.
BMDMswere isolated from the femurs of 16 week old wild-type C57BL/6
mice, as previously described (Mantuano et al., 2016). Bone marrow cells
were plated in 100-mm non-tissue culture-treated dishes (106 cells/well)
and cultured in DMEM/F-12 medium containing 10% FBS and 20% L929
cell-conditioned medium for 10 days. Non-adherent cells were eliminated
on day 10. Adherent cells included >95%BMDMs as determined by F4/80
and CD11b immunoreactivity (Mantuano et al., 2016, 2017).
All animal experiments were performed according to approved guidelines.
LRP1 gene silencing in PC12 cells
Rat LRP1-specific siRNA ON-TARGETplus SMARTpool (L-101489-02)
and NTC siRNA (D-001810-10) were from Dharmacon. PC12 cells (2×106)
were transfected with LRP1-specific or NTC siRNA (120 nM) by
electroporation using the Cell Line Nucleofector Kit V (Amaxa VCA-
1003). The extent of gene silencing was determined with immunoblot
analysis using an antibody specific for 85-kDa LRP1 β-chain (1:1000,
Abcam, Ab-215997). Immunoblots were subjected to densitometry.
Experiments were performed 36-48 h after transfection.
PAI1 activity assay
EA-tPA was incubated with PAI1, gPAI1, PAI1R76E or vehicle in 50 µl of
20 mM sodium phosphate, 150 mM NaCl, pH 7.4 (PBS) for 30 min.
EA-tPA was treated with AEBSF for 2 h. Plasminogen and S-2251 were
then added so the final volume was 150 µl. The final concentration of
EA-tPA (alone or in complex with PAI1) was 12 nM. The concentrations of
plasminogen and S-2251 were 0.2 µM and 0.2 mM, respectively. S-2251
hydrolysis was detected by monitoring the absorbance at 405 nm as a
function of time using a Spectramax M2 ELISA plate reader.
Analysis of cell signaling
PC12 cells were cultured in serum-containing medium until ∼70% confluent.
The cells were then transferred to serum-free medium (SFM) for 4 h and
treated with EA-tPA, AEBSF-treated EA-tPA, EA-tPA–PAI1 complex,
EA-tPA–gPAI1 complex, EA-tPA–PAI1R76E complex or free PAI1 for
10 min. In some studies, PC12 cells were pre-treated with 150 nM RAP or
1.0 μMMK801 for 30 min before adding candidate cell signaling activators.
PC12 cells that were transfected with LRP1-specific or NTC siRNA were
treated with EA-tPA or EA-tPA–PAI1 complex for 1 h.
SCs that were 70% confluent were transferred to SFM for 1 h and then
treated with EA-tPA or the EA-tPA–PAI1 complex for 1 h. BMDMs were
transferred to SFM for 30 min and then treated with LPS (0.1 µg/ml)
together with EA-tPA, tPA–PAI1 complex, free PAI1 or vehicle for 1 h.
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Extracts of PC12 cells, SCs and BMDMs were prepared in RIPA buffer
(PBS with 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS,
protease inhibitor mixture and phosphatase inhibitor mixture). The protein
concentration in cell extracts was determined with a bicinchoninic acid
assay. An equivalent amount of cellular protein (20–40 µg) was subjected
to 10% SDS-PAGE and electrotransferred to polyvinylidene fluoride
membranes. The membranes were blocked with 5% nonfat dried milk and
0.1% Tween 20 and incubated with primary antibodies from Cell Signaling
Technology that target: phospho-IκBα (1:1000, cat. 2859), total IκBα
(1:1000, 9242), phospho-ERK1/2 (1:2000, 4370), total-ERK1/2 (1:1000,
4695) and β-actin (1:5000, 3700). The membranes were washed and treated
with horseradish-peroxidase-conjugated secondary antibodies from Jackson
Laboratories (anti-rabbit IgG, 111-035-144; anti-mouse IgG, 15-035-146).
Immunoblots were developed using SuperSignal West Pico PLUS substrate
(Thermo Scientific) and imaged using Blue Devil autoradiography film
(Genesee Scientific) or the Azure Biosystems C300 system.
PC12 cell neurite outgrowth
PC12 cells were plated at 2×105 cells/well in six-well plates and maintained
in serum-containing medium for 24 h. The medium then was replaced with
SFM, and supplemented with tPA, preformed tPA–PAI1 complex, PAI1,
NGFβ or vehicle. Culturing was continued for 48 h; the medium and
added proteins were replaced after washing at 24 h. Neurite outgrowth
was assessed by phase-contrast microscopy using a Leica microscope
equipped with a DFC 300 digital camera and quantified using the ImageJ
plugin, NeuronJ.
SC migration
SC migration was studied using 6.5-mm Transwell chambers with 8 µm
pores (Corning), as previously described (Mantuano et al., 2015, 2008). The
bottom surface of each membrane was coated with 10 µg/ml fibronectin.
SCs in Satomedium (Bottenstein and Sato, 1980) supplemented with 1 mg/ml
BSA were pre-treated with EA-tPA (12 nM), EI-tPA (12 nM), tPA–PAI1
complex (12 nM), free PAI1 (36 nM), EI-tPA that was pre-incubated with
PAI1 or vehicle for 10 min at 37°C. The cells (104) were then transferred
to the upper Transwell chambers. The bottom chamber contained Sato
Medium with 1 mg/ml BSA, 10% FBS and the same proteins that were
added to the top chamber. Cell migration was allowed to occur for 4 h at 37°C
in 5% CO2. The upper surface of each membrane was cleaned with a cotton
swab. The membranes were then stained with PROTOCOL™ Hema 3™.
The number of cells on the bottom surface of each membrane was imaged
and counted using ImageJ. Five fields were examined on each filter.
Each condition was studied in quadruplicate.
RT-qPCR analysis of cytokine expression in BMDMs
BMDMs were transferred to SFM for 30 min and then treated with LPS
(0.1 µg/ml), EA-tPA, EA-tPA–PAI1 complex or PAI1, at the indicated
concentrations, alone or in combination for 6 h. RNAwas isolated using the
NucleoSpin RNA kit (Macherey-Nagel) and reverse-transcribed using the
iScript cDNA synthesis kit (Bio-Rad). qPCR was performed using TaqMan
gene expression products (Thermo Scientific). The mRNAs analyzed
included those encoding TNFα, IL-1β, IL-6 and CCL3. The relative change
in mRNA expression was calculated using the 2ΔΔCt method with GAPDH
mRNA as an internal normalizer.
Immunopurification of NMDA-R
C57BL/6micewere euthanizedwithCO2, according to a protocol approved by
the University of California San Diego Institutional Animal Care and
Use Committee. Cerebral cortices were harvested and then suspended
in ice-cold 50 mMTris-HCl, 150 mMNaCl, 1%NP40, pH. 8.0, supplemented
with proteinase inhibitor cocktail (Pierce) (IP buffer) and manually
dissociated using Biomasher (Omni) and vortexing. Extracts were cleared by
centrifugation at 13,000 g for 10 min, diluted five-fold in immunoprecipitation
buffferand thenpre-clearedby incubationwithProteinG–Dynabeads (Thermo
Scientific) in the absence of antibodies for 2 h at 4°C.
NMDA-R NR1 subunit-specific antibody (NR1-Ab) (Millipore; 05-432)
and non-specificmouse IgG (NS-IgG)were coupled to Protein-G–Dynabeads
by incubation for 30 min at 4°C. Antibody–Protein-G–Dynabeads conjugates
were stabilized by treatment with 5 mM bis(sulfosuccinimidyl)suberate for
30 min in PBS at room temperature. The crosslinking reaction was quenched
with 20 mM Tris-HCl pH 8. Pre-cleared mouse cortical extracts were
incubated with the antibody-conjugated Protein G–Dynabeads for 2 h at 4°C.
Binding of the NMDA-R to NR1-Ab and NS-IgG was determined by
immunoblot analysis. For these studies, antibody-associated proteins
were eluted in 100 mM glycine, pH 2.75 at 57°C while shaking in a
thermomixer at 800 rpm. The eluent was rapidly neutralized by adding
1.5 M Tris-HCl pH 8.0, and subsequently subjected to SDS-PAGE.
Following electro-transfer, membranes were probed with rabbit anti-NR1
antibody (1:500, Cell Signaling Technology, 5704) and detected using a
secondary horseradish peroxidase-conjugated antibody that specifically
recognizes rabbit IgG light chain (Jackson Laboratories; 115-035-174).
tPA-binding to immunopurified NMDA-R
EA-tPA was radioiodinated by incubation with 18.5 MBq of Na125I and
two Iodobeads (Pierce) for 15 min. 125I-EA-tPA was purified from free
Na125I by chromatography on Sephadex G25. The specific activity was 22
mCurie/g. 125I-EA-tPA (12 nM) and preformed 125I-EA-tPA–PAI1 complex
(12 nM) were incubated with NMDA-R that was immunocaptured by NR1-
Ab–Protein G–Dynabeads or with NS-IgG–Protein G–Dynabeads
conjugates, which were pre-incubated with mouse cortical extracts as a
control. The beads were washed three times with ice-cold PBS. The level of
antibody-associated 125I-EA-tPA was determined in a Wizard 1470 Gamma
Counter (Perkin Elmer).
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